Frontlight ResearchEarly access
Active, not recruitingNo phase
Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers
Key facts
- Who runs it
- LifeNet Health
- Where
- Aventura, Castro Valley, Decatur, Fresno, Hialeah, Katy, Miami, Raleigh, Rocky Mount, Salem, San Antonio, San Francisco, Springfield, Sugar Land, Tucson, and Vista, United StatesSee the 17 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 120 people, planned
- Started
- 26 Jun 2025
- Expected to end
- 30 Dec 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- Graft Application
- Wound Dressing Material
- Record updated
- 14 September 2026
Who can take part
- Age
- 21 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 34 criteriaShow less
Who can take part
- To be considered eligible to participate in this study, a subject must meet the inclusion criteria listed below:
- Be male or female and aged between 21 and 80 years at the time of informed consent
- Have a diagnosis of Type I or Type II diabetes as defined by the American Diabetes Association and have been on a stable anti-diabetic treatment regimen for at least 30 days before the baseline visit
- Have full-thickness wound of the lower extremity, below the ankle
- Have a single target ulcer
- Have a wound with an area greater than or equal to 1cm2 and less than 25 cm2 with a depth less than or equal to 9 mm
- Have a diabetic foot ulcer that has been present for at least 30 days with a Wagner Classification Grade 1 or 2:; Grade 1: superficial diabetic ulcer involving the full skin thickness but not underlying tissues; Grade 2: ulcer extension involving ligament, tendon, joint capsule, or fascia, without presence of abscess or osteomyelitis
- Have an absence of infection based on Infectious Disease Society of America criteria (assessed at BOTH Screening/Visit 1 and Baseline/Visit 2)
- Have an adequate circulation to the affected lower extremity, defined as at least one of the criteria within the previous 60 days:; Transcutaneous oxygen measurement at the dorsum of the foot greater or equal to 30 mm Hg; Ankle-brachial index (ABI) ranging from 0.8 to 1.2; At least biphasic Doppler arterial waveforms at the dorsalis pedis and posterior tibial arteries
- Have the ability to comply with off-loading and dressing change requirements
- Have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an informed consent form (ICF) approved by an institutional review board (IRB), and agree to abide by the study restrictions and return to the site for the required assessments
- Have provided written authorization for use and disclosure of protected health information
- Have a life expectancy of greater than 6 months
Who cannot take part
- Have the wound treated with biomedical or topical growth factors within the previous 30 days before the Screening Visit
- Need for any additional concomitant dressing material other than the ones approved for this study
- Had a treatment with immunosuppressive or chemotherapeutic agents, radiotherapy or systemic corticosteroids less than 30 days before the Baseline Visit
- Has undergone a revascularization procedure aimed at increasing blood flow in the treatment target limb less than 4 weeks before the Baseline Visit
- Have undergone treatment with a living skin equivalent within the last 4 weeks before screening
- Have clinical signs of an infection at the study ulcer site (assessed at BOTH Screening/Visit 1 and Baseline/Visit 2)
- Have a known or suspected disease of the immune system
- Have an active or untreated malignancy or active, uncontrolled connective tissue disease
- Have active Charcot disease
- Have ongoing evidence of peripheral vascular disease, including greater than one nonpalpable pulse on either foot
- Have the presence of any condition that in the opinion of the investigator places the subject at undue risk or potentially jeopardizes the quality of the data to be generated
- Have a circulating hemoglobin A1c exceeding 12% within 90 days of the Screening Visit (assessed at Screening/Visit 1 for subjects with labs collected <30 days of screening; assessed at Baseline/Visit 2 for subjects with labs collected at screening)
- Have a serum creatinine concentration of 3.0 mg/dL or greater within 30 days prior to screening (assessed at Screening/Visit 1 for subjects with labs collected <30 days of screening; assessed at Baseline/Visit 2 for subjects with labs collected at screening)
- Have serum aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase levels greater than three times the normal upper limit within 30 days prior to screening (assessed at Screening/Visit 1 if subject had labs collected <30 days of screening; assessed at Baseline/Visit 2 if subject had labs collected at screening)
- To be eligible for entry into the study, the subject must not meet any of the exclusion criteria listed below:
- Be pregnant or lactating
- Subjects with a target wound <30 days old at Screening whose wound area has decreased in size ≥50% between the Screening and Baseline Visits (assessed at Baseline/Visit 2)
- Have a sensitivity to either of the following antibiotics: lincomycin, gentamicin, polymyxin B, or vancomycin
- Have a sensitivity to polysorbate 20, N-lauroyl sarcosinate, benzonase or glycerol
- Have the inability to tolerate an off-loading boot
- Have presence of necrosis, purulence, or sinus tracts that cannot be removed by debridement (assessed at Baseline/Visit 2)
Where in United States
- Humanity Clinical Research, CorpAventura, United States
- Bay Area Foot CareCastro Valley, United States
- Independent Clinical ResearchDecatur, United States
- Limb Preservaion Platform, Inc.Fresno, United States
- Dinamo Research & Diagnostic Center, LLCHialeah, United States
- Olympus Clinical ResearchKaty, United States
- Doctors Research Network, Inc.Miami, United States
- US Foot and Ankle SpecialistsRaleigh, United States
- Foot and Ankle Institute of the CarolinasRocky Mount, United States
- Foot and Ankle Specialists of the Mid-AtlanticSalem, United States
- Element Research GroupSan Antonio, United States
- Bay Area Foot CareSan Francisco, United States
- Center for Clinical Research Inc.San Francisco, United States
- Independent Clinical Research, LLCSpringfield, United States
- Olympus-AlcanzaSugar Land, United States
- Compass Medical Research CenterTucson, United States
- ILD Research CenterVista, United States
About the trial
What the trial wants to find out
This study will evaluate Matrion™ (LifeNet Health, Inc., Virginia Beach, VA), a placental membrane product, as a treatment for diabetic foot ulcers compared to conventional wound care. Matrion is derived from donated human birth tissue and includes both the amniotic and chorionic layers, along with the trophoblast layer. It is minimally processed using a proprietary decellularization method and terminally sterilized to ensure the membrane is acellular and sterile, making it suitable for surgical applications.
The 2 groups in the trial
- Arm 1:Other group
Matrion
Treatment: Graft Application
- Arm 2Other group
Conventional Wound Management
Treatment: Wound Dressing Material
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open-Label Trial to Assess the Clinical Effectiveness of Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers
- Record updated
- 14 September 2026